Cystic Fibrosis News

Patients with cystic fibrosis had improved chronic rhinosinusitis outcomes after 1 year of elexacaftor/tezacaftor/ivacaftor therapy, according to results published in JAMA Otolaryngology-Head & Neck Surgery.

Elexacaftor/tezacaftor/ivacaftor appeared safe and well tolerated among kids aged 12 years and older with cystic fibrosis and either F508del/minimal function or F508del/F508del genotypes for up to 144 weeks, according to study results.

Yearly paranasal sinus MRI imaging allowed physicians to track chronic rhinosinusitis development in children with cystic fibrosis, according to results published in Annals of the American Thoracic Society.

The FDA granted orphan drug designation to ARCT-032 as a treatment for patients with cystic fibrosis, according to a press release from Arcturus Therapeutics.

In kids aged 6 years and older with cystic fibrosis and either F508del/minimal function or F508del/F508del genotypes, elexacaftor/tezacaftor/ivacaftor was safe and well tolerated for up to 120 weeks, according to study results.

Receipt of 4D-710, an aerosolized gene therapy, resulted in high cystic fibrosis transmembrane conductance regulator protein expression levels in patients with cystic fibrosis, according to a company press release.

For patients with cystic fibrosis, exercise helps with disease management, and exercise tests allow clinicians to assess lung health, muscle strength and treatment response, according to a press release from University of Portsmouth.

Among patients with cystic fibrosis, increases in sulfate and specific metals in water raised the odds for nontuberculosis mycobacterial infections, according to results published in Environmental Epidemiology.

Infants with cystic fibrosis who received care at 47 days old had decreased weight and height-for-age during infancy compared with infants who received care at 10 days old, according to results published in The Journal of Pediatrics.

Patients with cystic fibrosis had an average survival of 66 years in 2022, which is a notable increase from 26 years in 2008, according to study results from Epic Research.